Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 948.03M | 995.55M | 871.80M | 1.54B | 1.54B | 1.25B |
Gross Profit | 918.56M | 968.29M | 830.23M | 1.50B | 1.51B | 1.22B |
EBITDA | 1.59B | 840.60M | 697.41M | 1.35B | 1.37B | 1.10B |
Net Income | -1.65B | -2.41B | -556.48M | 902.60M | 656.02M | 431.45M |
Balance Sheet | ||||||
Total Assets | 14.85B | 14.29B | 18.30B | 19.66B | 20.52B | 16.83B |
Cash, Cash Equivalents and Short-Term Investments | 673.48M | 332.33M | 250.02M | 235.67M | 459.23M | 549.88M |
Total Debt | 9.47B | 8.93B | 10.22B | 11.34B | 11.44B | 9.01B |
Total Liabilities | 10.09B | 9.46B | 10.67B | 11.06B | 12.07B | 9.49B |
Stockholders Equity | 4.76B | 4.83B | 7.63B | 8.59B | 8.44B | 7.34B |
Cash Flow | ||||||
Free Cash Flow | 171.53M | 245.48M | 505.79M | -801.35M | 746.11M | -3.67B |
Operating Cash Flow | 171.53M | 245.48M | 505.79M | 739.01M | 811.66M | 617.64M |
Investing Cash Flow | 1.35B | 1.32B | 517.56M | 396.06M | -3.86B | -2.95B |
Financing Cash Flow | -1.08B | -1.48B | -1.02B | -1.34B | 2.95B | 1.40B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $3.61B | 24.31 | 10.49% | 4.68% | 6.87% | 7.23% | |
74 Outperform | $4.53B | 24.87 | 6.66% | 6.17% | 6.89% | 240.70% | |
73 Outperform | $1.66B | 19.70 | 8.94% | 6.29% | 8.18% | -16.83% | |
71 Outperform | $1.37B | 34.91 | 2.71% | 6.35% | 0.43% | 58.57% | |
64 Neutral | $512.95M | 104.75 | 1.94% | 11.16% | 0.90% | ― | |
62 Neutral | AU$3.09B | 14.60 | 3.06% | 4.99% | 25.15% | 80.76% | |
49 Neutral | $2.55B | ― | -25.97% | 7.39% | 27.66% | 18.03% |
On August 11, 2025, Medical Properties entered into an equity distribution agreement with several financial institutions to offer and sell up to $500 million in common stock. This agreement allows for various types of transactions, including at-the-market offerings and forward sale transactions, with the company potentially receiving proceeds upon settlement. The company may choose different settlement options, which could impact the proceeds received.
On June 2, 2025, Medical Properties, along with its subsidiaries, filed a Registration Statement with the SEC, updating the U.S. Federal Income Tax Considerations for its REIT status. The filing outlines the tax implications for the company and its stakeholders, emphasizing the benefits and potential liabilities associated with its REIT classification, including the avoidance of double taxation and the conditions under which it may incur federal taxes.
Medical Properties Trust, Inc. held its annual meeting of stockholders on May 29, 2025. During this meeting, nine directors were elected to the board, PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and a non-binding advisory vote on executive compensation was approved.